8-K Announcements
6Material company update
May 11, 2026·SEC
Material company update
May 7, 2026·SEC
Material company update
Mar 18, 2026·SEC
Catalyst Pharmaceuticals, Inc.(CPRX)Earnings, Financials & Key Ratios
CPRX•NASDAQ
18.7× P/E·Price updated Jun 19, 2026
AboutCatalyst Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients. The company also develops Firdapse for the treatment of MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3, as well as to treat hereditary neuropathy with liability to pressure palsies. It has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.Show more
- Revenue$589M+19.8%
- EBITDA$296M+26.9%
- Net Income$214M+30.8%
- EPS (Diluted)1.68+28.2%
- Gross Margin85.19%-0.9%
- EBITDA Margin50.2%+6.0%
- Operating Margin43.77%+10.3%
- Net Margin36.39%+9.2%
- ROE25.49%-13.3%
CPRX Key Insights
Catalyst Pharmaceuticals, Inc. (CPRX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Excellent 3Y average ROE of 25.2%
- ✓Strong 5Y profit CAGR of 23.4%
- ✓FCF machine: 35.4% free cash flow margin
- ✓Momentum leader: RS Rating 86 (top 14%)
- ✓Strong 5Y sales CAGR of 37.7%
✗Weaknesses
No significant weaknesses identified
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when CPRX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CPRX Price & Volume
Catalyst Pharmaceuticals, Inc. (CPRX) stock price & volume — 10-year historical chart
Loading chart...
CPRX Growth Metrics
Catalyst Pharmaceuticals, Inc. (CPRX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years37.68%
3 Years40.1%
TTM11.65%
Profit CAGR
10 Years-
5 Years23.37%
3 Years37.15%
TTM12.15%
EPS CAGR
10 Years-
5 Years18.8%
3 Years30.84%
TTM10.19%
Return on Capital
10 Years10.89%
5 Years31.13%
3 Years29.86%
Last Year30.5%
CPRX Recent Earnings
Catalyst Pharmaceuticals, Inc. (CPRX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 11/12 qtrs (92%)●Beat Revenue 7/12 qtrs (58%)
Q2 2026Latest
May 11, 2026Metric
Actual
Est
EPS
$0.74+15.6%
$0.64
Rev
$149M-0.1%
$150M
Q1 2026
Feb 25, 2026Metric
Actual
Est
EPS
$0.68+61.9%
$0.42
Rev
$153M+6.8%
$143M
Q4 2025
Nov 5, 2025Metric
Actual
Est
EPS
$0.68+33.3%
$0.51
Rev
$148M+4.0%
$143M
Q3 2025
Aug 6, 2025Metric
Actual
Est
EPS
$0.68+17.2%
$0.58
Rev
$147M+4.4%
$140M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $0.74vs $0.64+15.6% | $149Mvs $150M-0.1% |
| Q1 2026 | Feb 25, 2026 | $0.68vs $0.42+61.9% | $153Mvs $143M+6.8% |
| Q4 2025 | Nov 5, 2025 | $0.68vs $0.51+33.3% | $148Mvs $143M+4.0% |
| Q3 2025 | Aug 6, 2025 | $0.68vs $0.58+17.2% | $147Mvs $140M+4.4% |
Based on last 12 quarters of dataView full earnings history →
CPRX Peer Comparison
Catalyst Pharmaceuticals, Inc. (CPRX) competitors in Commercial Rare Disease Biopharma — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RARE | 2.7B | 27.44 | -4.71 | 20.13% | -91.03% | -6.08% | ||
 FOLD | 4.55B | 14.49 | -164.85 | 20.05% | -4.27% | -12.02% | 1.76 | |
 ACAD | 3.7B | 21.62 | 9.44 | 11.87% | 34.3% | 35.65% | 0.04 | |
 PTCT | 6.55B | 78.98 | 10.15 | 114.51% | -22.58% | |||
 MDGL | 11.66B | 505.75 | -39.36 | 432.05% | -27.32% | -50.15% | 0.59 | |
 PRAX | 8.15B | 282.31 | -20.94 | -100% | -43.02% | 0.00 | ||
 ALKS | 7.5B | 44.99 | 31.46 | -5.25% | 9.78% | 8.82% | 0.04 | |
 SUPN | 2.56B | 44.38 | -65.26 | 8.63% | -3.74% | -2.73% | 0.04 |
Compare CPRX vs Peers
Catalyst Pharmaceuticals, Inc. (CPRX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CPRX Income Statement
Catalyst Pharmaceuticals, Inc. (CPRX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 500K | 102.31M | 119.07M | 140.83M | 214.2M | 398.2M | 491.73M | 588.99M | 596.96M |
Revenue Growth % | - | - | 20361.2% | 16.39% | 18.27% | 52.1% | 85.9% | 23.49% | 19.78% | 11.65% |
Cost of Goods Sold | 45.69K | 19.92M | 14.76M | 17.04M | 21.88M | 34.39M | 51.97M | 68.84M | 87.25M | 105.52M |
COGS % of Revenue | - | 3983.84% | 14.43% | 14.31% | 15.54% | 16.06% | 13.05% | 14% | 14.81% | - |
Gross Profit | -45.69K▲ 0% | -19.42M▼ 42403.0% | 87.55M▲ 550.8% | 102.03M▲ 16.5% | 118.95M▲ 16.6% | 179.81M▲ 51.2% | 346.24M▲ 92.6% | 422.89M▲ 22.1% | 501.74M▲ 18.6% | 491.44M▲ 0% |
Gross Margin % | - | -3883.84% | 85.57% | 85.69% | 84.46% | 83.94% | 86.95% | 86% | 85.19% | 82.32% |
Gross Profit Growth % | -5.26% | -42403.02% | 550.83% | 16.55% | 16.58% | 51.17% | 92.56% | 22.14% | 18.64% | - |
Operating Expenses | 18.68M | 35.8M | 55.72M | 60.73M | 66.56M | 77.97M | 259.43M | 227.76M | 243.96M | 223.79M |
OpEx % of Revenue | - | 7159.03% | 54.47% | 51% | 47.26% | 36.4% | 65.15% | 46.32% | 41.42% | - |
Selling, General & Admin | 7.3M | 15.88M | 36.88M | 44.23M | 49.63M | 57.09M | 133.71M | 177.74M | 193.75M | 196.16M |
SG&A % of Revenue | - | 3175.19% | 36.05% | 37.15% | 35.24% | 26.65% | 33.58% | 36.15% | 32.9% | - |
Research & Development | 11.38M | 19.92M | 18.84M | 16.5M | 16.94M | 19.79M | 93.15M | 12.65M | 12.71M | 11.48M |
R&D % of Revenue | - | 3983.84% | 18.42% | 13.85% | 12.03% | 9.24% | 23.39% | 2.57% | 2.16% | - |
Other Operating Expenses | 0 | 1.29M | 0 | 0 | 0 | 1.1M | 32.56M | 37.38M | 37.5M | 2M |
Operating Income | -18.68M▲ 0% | -35.3M▼ 88.9% | 31.82M▲ 190.2% | 41.3M▲ 29.8% | 52.38M▲ 26.8% | 101.84M▲ 94.4% | 86.81M▼ 14.8% | 195.12M▲ 124.8% | 257.78M▲ 32.1% | 267.64M▲ 0% |
Operating Margin % | - | -7059.03% | 31.11% | 34.69% | 37.2% | 47.54% | 21.8% | 39.68% | 43.77% | 44.83% |
Operating Income Growth % | 3.11% | -88.95% | 190.16% | 29.79% | 26.83% | 94.4% | -14.75% | 124.77% | 32.11% | - |
EBITDA | -18.63M | -35.26M | 31.88M | 41.4M | 52.58M | 103.08M | 119.69M | 232.9M | 295.65M | 305.91M |
EBITDA Margin % | - | -7051.44% | 31.16% | 34.76% | 37.33% | 48.12% | 30.06% | 47.36% | 50.2% | 51.24% |
EBITDA Growth % | 3.13% | -89.21% | 190.42% | 29.85% | 27.01% | 96.05% | 16.12% | 94.58% | 26.94% | 17.78% |
D&A (Non-Cash Add-back) | 45.69K | 37.98K | 55K | 92K | 192K | 1.24M | 32.88M | 37.77M | 37.87M | 38.26M |
EBIT | -18.41M | -35.3M | 31.82M | 41.3M | 52.38M | 101.84M | 86.81M | 195.12M | 257.78M | 275.41M |
Net Interest Income | 0 | 1.29M | 1.59M | 0 | 0 | 0 | 0 | 16.06M | 0 | 12.19M |
Interest Income | 454.16K | 1.29M | 1.59M | 0 | 0 | 0 | 0 | 16.06M | 0 | 12.19M |
Interest Expense | 454.16K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Income/Expense | 267.26K | 1.29M | 1.59M | 587K | 282K | 2.88M | 7.7M | 21.14M | 25.74M | 28.82M |
Pretax Income | -18.41M▲ 0% | -34M▼ 84.7% | 33.41M▲ 198.3% | 41.89M▲ 25.4% | 52.67M▲ 25.7% | 104.72M▲ 98.8% | 94.51M▼ 9.7% | 216.26M▲ 128.8% | 283.51M▲ 31.1% | 296.46M▲ 0% |
Pretax Margin % | - | -6800.7% | 32.66% | 35.18% | 37.4% | 48.89% | 23.73% | 43.98% | 48.14% | 49.66% |
Income Tax | 141.22K | 0 | 1.53M | -33.09M | 13.19M | 21.64M | 23.1M | 52.37M | 69.19M | 75.14M |
Effective Tax Rate % | -0.77% | 0% | 4.59% | -79% | 25.03% | 20.66% | 24.44% | 24.22% | 24.4% | 25.34% |
Net Income | -18.41M▲ 0% | -34M▼ 84.7% | 31.88M▲ 193.7% | 74.98M▲ 135.2% | 39.48M▼ 47.3% | 83.08M▲ 110.4% | 71.41M▼ 14.0% | 163.89M▲ 129.5% | 214.33M▲ 30.8% | 221.32M▲ 0% |
Net Margin % | - | -6800.7% | 31.16% | 62.97% | 28.03% | 38.79% | 17.93% | 33.33% | 36.39% | 37.08% |
Net Income Growth % | -1.88% | -84.68% | 193.74% | 135.24% | -47.35% | 110.42% | -14.05% | 129.5% | 30.78% | 12.15% |
Net Income (Continuing) | -18.41M | -34M | 31.88M | 74.98M | 39.48M | 83.08M | 71.41M | 163.89M | 214.33M | 221.32M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.21▲ 0% | -0.33▼ 57.1% | 0.30▲ 190.9% | 0.71▲ 136.7% | 0.37▼ 47.9% | 0.75▲ 102.7% | 0.63▼ 16.0% | 1.31▲ 107.9% | 1.68▲ 28.2% | 1.74▲ 0% |
EPS Growth % | 4.55% | -57.14% | 190.91% | 136.67% | -47.89% | 102.7% | -16% | 107.94% | 28.24% | 10.19% |
EPS (Basic) | -0.21 | -0.33 | 0.31 | 0.72 | 0.38 | 0.80 | 0.67 | 1.38 | 1.75 | - |
Diluted Shares Outstanding | 85.8M | 102.63M | 106.02M | 106.24M | 107.8M | 111.38M | 113.75M | 124.94M | 127.26M | 126.9M |
Basic Shares Outstanding | 85.8M | 102.63M | 102.94M | 103.51M | 103.38M | 103.37M | 106.28M | 118.46M | 122.29M | 122.25M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
CPRX Balance Sheet
Catalyst Pharmaceuticals, Inc. (CPRX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 85.19M | 55.19M | 111.36M | 159.24M | 210.11M | 320.81M | 219.33M | 623.61M | 894.03M | 940.39M |
Cash & Short-Term Investments | 84.01M | 53.48M | 94.52M | 140.28M | 191.27M | 298.39M | 137.64M | 517.55M | 709.17M | 755.86M |
Cash Only | 57.5M | 16.56M | 89.51M | 130.24M | 171.44M | 298.39M | 137.64M | 517.55M | 709.17M | 755.86M |
Short-Term Investments | 26.52M | 36.92M | 5.01M | 10.04M | 19.82M | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 0 | 0 | 10.54M | 5.99M | 6.72M | 10.79M | 53.51M | 65.49M | 128.27M | 131.31M |
Days Sales Outstanding | - | - | 37.59 | 18.35 | 17.43 | 18.39 | 49.05 | 48.61 | 79.49 | 66.13 |
Inventory | 0 | 56.01K | 1.96M | 4.65M | 7.87M | 6.8M | 15.64M | 19.54M | 37.17M | 34.93M |
Days Inventory Outstanding | - | 1.03 | 48.39 | 99.63 | 131.26 | 72.22 | 109.88 | 103.6 | 155.47 | 102.71 |
Other Current Assets | 58.28K | 272.17K | 516.66K | 883K | 327K | 0 | 489K | 1.03M | 2.04M | 2.72M |
Total Non-Current Assets | 200.27K | 5.26M | 1.01M | 33.11M | 27.68M | 54.82M | 250.78M | 227.8M | 212.78M | 207.22M |
Property, Plant & Equipment | 191.38K | 245.43K | 1M | 130K | 3.98M | 3.62M | 3.7M | 3.58M | 2.97M | 2.85M |
Fixed Asset Turnover | - | 2.04x | 101.93x | 915.95x | 35.42x | 59.22x | 107.54x | 137.20x | 198.18x | 196.63x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 32.47M | 194.05M | 156.67M | 131.67M | 121.97M |
Long-Term Investments | 0 | 5.01M | 0 | 0 | 0 | 0 | 16.49M | 21.56M | 22.54M | 90.25M |
Other Non-Current Assets | 8.89K | 8.89K | 8.89K | 9K | 9K | 0 | 0 | 0 | 0 | 0 |
Total Assets | 85.39M▲ 0% | 60.45M▼ 29.2% | 112.38M▲ 85.9% | 192.35M▲ 71.2% | 237.79M▲ 23.6% | 375.63M▲ 58.0% | 470.11M▲ 25.2% | 851.41M▲ 81.1% | 1.11B▲ 30.0% | 1.15B▲ 0% |
Asset Turnover | - | 0.01x | 0.91x | 0.62x | 0.59x | 0.57x | 0.85x | 0.58x | 0.53x | 0.56x |
Asset Growth % | 104.73% | -29.21% | 85.9% | 71.17% | 23.62% | 57.97% | 25.15% | 81.11% | 30% | 130.08% |
Total Current Liabilities | 4.27M | 9.51M | 24.1M | 22.76M | 27.06M | 57.59M | 76.06M | 120.68M | 147.15M | 132.4M |
Accounts Payable | 1.95M | 2.34M | 4.12M | 4.26M | 2.77M | 3.98M | 14.79M | 16.59M | 11.2M | 7.15M |
Days Payables Outstanding | 15.54K | 42.83 | 101.83 | 91.17 | 46.17 | 42.19 | 103.92 | 87.97 | 46.86 | 28.52 |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 437K | 446K |
Deferred Revenue (Current) | 24.01K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1.5M | 2.04M | 3.24M | 4.1M | 4.28M | 5.37M | 51.29M | 11.16M | 122.76M | 98.65M |
Current Ratio | 19.97x | 5.80x | 4.62x | 7.00x | 7.76x | 5.57x | 2.88x | 5.17x | 6.08x | 7.10x |
Quick Ratio | 19.97x | 5.80x | 4.54x | 6.79x | 7.47x | 5.45x | 2.68x | 5.01x | 5.82x | 6.84x |
Cash Conversion Cycle | - | - | -15.84 | 26.81 | 102.52 | 48.42 | 55.01 | 64.24 | 188.1 | 140.33 |
Total Non-Current Liabilities | 157.46K | 154.8K | 647.53K | 0 | 3.89M | 17.62M | 6.17M | 3.1M | 5.39M | 2.52M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 0 | 647.53K | 0 | 3.89M | 3.56M | 3.19M | 2.79M | 2.35M | 9.62M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.83M | 2.83M |
Other Non-Current Liabilities | 157.46K | 154.8K | 0 | 0 | 0 | 14.06M | 2.98M | 315K | 209K | 280K |
Total Liabilities | 4.42M | 9.67M | 24.75M | 22.76M | 30.96M | 75.21M | 82.23M | 123.78M | 152.54M | 134.91M |
Total Debt | 0 | 0 | 948.05K | 29K | 4.2M | 3.89M | 3.56M | 3.19M | 2.79M | 2.68M |
Net Debt | -57.5M | -16.56M | -88.56M | -130.21M | -167.24M | -294.5M | -134.08M | -514.37M | -706.38M | -753.18M |
Debt / Equity | - | - | 0.01x | 0.00x | 0.02x | 0.01x | 0.01x | 0.00x | 0.00x | 0.00x |
Debt / EBITDA | - | - | 0.03x | 0.00x | 0.08x | 0.04x | 0.03x | 0.01x | 0.01x | 0.01x |
Net Debt / EBITDA | - | - | -2.78x | -3.15x | -3.18x | -2.86x | -1.12x | -2.21x | -2.39x | -2.46x |
Interest Coverage | -40.54x | - | - | - | - | - | - | - | - | - |
Total Equity | 80.96M▲ 0% | 50.78M▼ 37.3% | 87.63M▲ 72.6% | 169.6M▲ 93.5% | 206.83M▲ 22.0% | 300.42M▲ 45.2% | 387.88M▲ 29.1% | 727.63M▲ 87.6% | 954.27M▲ 31.1% | 1.01B▲ 0% |
Equity Growth % | 105.97% | -37.28% | 72.55% | 93.54% | 21.95% | 45.25% | 29.11% | 87.59% | 31.15% | 138.52% |
Book Value per Share | 0.94 | 0.49 | 0.83 | 1.60 | 1.92 | 2.70 | 3.41 | 5.82 | 7.50 | 7.98 |
Total Shareholders' Equity | 80.96M | 50.78M | 87.63M | 169.6M | 206.83M | 300.42M | 387.88M | 727.63M | 954.27M | 1.01B |
Common Stock | 102.55K | 102.74K | 103.4K | 104K | 103K | 105K | 107K | 121K | 123K | 122K |
Retained Earnings | -126.56M | -160.56M | -128.69M | -53.7M | -26.31M | 49.86M | 121.27M | 285.16M | 474.19M | 523.35M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -159.17K | -20.25K | 9.51K | 31K | -148K | 24K | 14K | 64K | 0 | 8K |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CPRX Cash Flow Statement
Catalyst Pharmaceuticals, Inc. (CPRX) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -13.74M | -25.7M | 34.61M | 45.03M | 60.37M | 116.05M | 143.6M | 239.81M | 208.67M | 208.21M |
Operating CF Margin % | - | -5140.88% | 33.83% | 37.82% | 42.87% | 54.18% | 36.06% | 48.77% | 35.43% | - |
Operating CF Growth % | 23.5% | -87.04% | 234.65% | 30.12% | 34.06% | 92.22% | 23.74% | 67% | -12.98% | -81.74% |
Net Income | -18.41M | -34M | 31.88M | 74.98M | 39.48M | 83.08M | 71.41M | 163.89M | 214.33M | 221.32M |
Depreciation & Amortization | 45.69K | 37.98K | 297.73K | 885.32K | 192K | 1.24M | 32.88M | 37.77M | 37.87M | 38.26M |
Stock-Based Compensation | 2.41M | 3.55M | 0 | 0 | 6.07M | 7.91M | 14.25M | 22.25M | 24.78M | 18.93M |
Deferred Taxes | 0 | 0 | 0 | -32.97M | 9.32M | 4.94M | -17.82M | -9.39M | -6.85M | -6.86M |
Other Non-Cash Items | 186.9K | 3.68M | 3.53M | 6.25M | 287K | 5.16M | 80.2M | -5.63M | -563K | 3.44M |
Working Capital Changes | 2.03M | 4.71M | -1.1M | -4.11M | 5.02M | 13.73M | -37.32M | 30.91M | -60.9M | -66.88M |
Change in Receivables | 0 | 0 | -10.54M | 4.55M | -632K | -3.82M | -43.08M | -11.96M | -61M | -59.57M |
Change in Inventory | 0 | -56.01K | -1.9M | -2.69M | -3.22M | 1.06M | -4.74M | -3.9M | -18.09M | -15.62M |
Change in Payables | 1.01M | 391.79K | 1.78M | 138.57K | -1.49M | 1.21M | 10.82M | 1.8M | -5.39M | -4.05M |
Cash from Investing | -3.96K | -15.53M | 37.22M | -5.01M | -11.02M | 9.21M | -293.5M | -556K | -58K | -85K |
Capital Expenditures | 0 | -92.02K | -19.37K | -11.4K | -1.02M | -29K | -231K | -556K | -58K | -85K |
CapEx % of Revenue | - | 18.4% | 0.02% | 0.01% | 0.73% | 0.01% | 0.06% | 0.11% | 0.01% | 0.01% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 10M | 0 | 0 | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | -3.96K | -14.99M | 0 | 0 | 0 | -10M | -279.81M | 0 | 0 | 0 |
Cash from Financing | 57.35M | 293.12K | 1.12M | 701.93K | -8.14M | 1.69M | -10.86M | 140.66M | -16.99M | -32.93M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 53.77M | 0 | 1.12M | 758.13K | -12.09M | -6.91M | 0 | 140.7M | -10.63M | -32.49M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | -4.45K | 0 | 0 | -12.09M | -6.91M | 0 | -296K | -25.3M | -39.87M |
Other Financing | 3.58M | 293.12K | 0 | -56.2K | 3.95M | 8.6M | -10.86M | -39K | -6.36M | -440K |
Net Change in Cash | 43.6M▲ 0% | -40.94M▼ 193.9% | 72.95M▲ 278.2% | 40.73M▼ 44.2% | 41.21M▲ 1.2% | 126.95M▲ 208.1% | -160.76M▼ 226.6% | 379.92M▲ 336.3% | 191.62M▼ 49.6% | 175.2M▲ 0% |
Free Cash Flow | -13.74M▲ 0% | -25.8M▼ 87.7% | 34.59M▲ 234.1% | 45.02M▲ 30.2% | 59.35M▲ 31.8% | 116.02M▲ 95.5% | 61.86M▼ 46.7% | 239.25M▲ 286.8% | 208.61M▼ 12.8% | 208.13M▲ 0% |
FCF Margin % | - | -5159.28% | 33.81% | 37.81% | 42.14% | 54.16% | 15.53% | 48.65% | 35.42% | 34.86% |
FCF Growth % | 23.9% | -87.71% | 234.1% | 30.16% | 31.82% | 95.48% | -46.68% | 286.79% | -12.81% | -22.21% |
FCF per Share | -0.16 | -0.25 | 0.33 | 0.42 | 0.55 | 1.04 | 0.54 | 1.91 | 1.64 | 1.64 |
FCF Conversion (FCF/Net Income) | 0.75x | 0.76x | 1.09x | 0.60x | 1.53x | 1.40x | 2.01x | 1.46x | 0.97x | 0.94x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 705K | 1.4M | 0 | 233K |
Taxes Paid | 0 | 0 | 0 | 0 | 3M | 7.67M | 50.46M | 68.45M | 0 | 54.5M |
CPRX Key Ratios
Catalyst Pharmaceuticals, Inc. (CPRX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | -30.62% | -51.62% | 46.06% | 58.3% | 20.98% | 32.76% | 20.75% | 29.38% | 25.49% | 23.65% |
Return on Invested Capital (ROIC) | -57.32% | -91.77% | 143.39% | 161.1% | 99.49% | 335.67% | 50.14% | 62.66% | 83.85% | 84.8% |
Gross Margin | - | -3883.84% | 85.57% | 85.69% | 84.46% | 83.94% | 86.95% | 86% | 85.19% | 82.32% |
Net Margin | - | -6800.7% | 31.16% | 62.97% | 28.03% | 38.79% | 17.93% | 33.33% | 36.39% | 37.08% |
Debt / Equity | - | - | 0.01x | 0.00x | 0.02x | 0.01x | 0.01x | 0.00x | 0.00x | 0.00x |
Interest Coverage | -40.54x | - | - | - | - | - | - | - | - | - |
FCF Conversion | 0.75x | 0.76x | 1.09x | 0.60x | 1.53x | 1.40x | 2.01x | 1.46x | 0.97x | 0.94x |
Revenue Growth | - | - | 20361.2% | 16.39% | 18.27% | 52.1% | 85.9% | 23.49% | 19.78% | 11.65% |
Related:CPRX Dividend History·CPRX Revenue History·CPRX Price History·CPRX P/E History·CPRX Financial Ratios·CPRX Institutional Holders
CPRX SEC Filings & Documents
Catalyst Pharmaceuticals, Inc. (CPRX) SEC filings — annual & quarterly reports (10-K, 10-Q)
CPRX Frequently Asked Questions
Catalyst Pharmaceuticals, Inc. (CPRX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Catalyst Pharmaceuticals, Inc. (CPRX) reported $597.0M in revenue for fiscal year 2025.
Catalyst Pharmaceuticals, Inc. (CPRX) grew revenue by 19.8% over the past year. This is strong growth.
Yes, Catalyst Pharmaceuticals, Inc. (CPRX) is profitable, generating $221.3M in net income for fiscal year 2025 (36.4% net margin).
Dividend & Returns
Catalyst Pharmaceuticals, Inc. (CPRX) has a return on equity (ROE) of 25.5%. This is excellent, indicating efficient use of shareholder capital.
Catalyst Pharmaceuticals, Inc. (CPRX) generated $208.1M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.